急性补充胆碱对低、中、高表现健康志愿者的神经认知影响。
Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers.
作者信息
Knott Verner, de la Salle Sara, Choueiry Joelle, Impey Danielle, Smith Dylan, Smith Meaghan, Beaudry Elise, Saghir Salman, Ilivitsky Vadim, Labelle Alain
机构信息
University of Ottawa Institute of Mental Health Research, Ottawa, ON, Canada; Department of Cellular and Molecular Medicine, Neuroscience Program, University of Ottawa, Ottawa, ON, Canada; School of Psychology, University of Ottawa, Ottawa, ON, Canada; Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
School of Psychology, University of Ottawa, Ottawa, ON, Canada.
出版信息
Pharmacol Biochem Behav. 2015 Apr;131:119-29. doi: 10.1016/j.pbb.2015.02.004. Epub 2015 Feb 12.
Novel pharmacological treatments targeting alpha 7 nicotinic acetylcholine receptor (α7 nAChR) hypofunction in schizophrenia have shown mixed success in ameliorating cognitive impairments associated with this disorder. Choline, a selective agonist at α7 receptors is increased with oral administration of cytidine 5'-diphosphocholine (CDP-choline), the cognitive effects of which were assessed in healthy volunteers. Using the CogState test battery, behavioral performance in schizophrenia-relevant cognitive domains was assessed in 24 male participants following a single low (500mg) and moderate (1000mg) dose of CDP-choline. Relative to placebo, CDP-choline improved processing speed, working memory, verbal learning, verbal memory, and executive function in low baseline performers, while exerting no effects in medium baseline performers, and diminishing cognition in high baseline performers. Dose effects varied with cognitive domain but were evident with both the 500mg and 1000mg doses. These preliminary findings of cognitive enhancement in relatively impaired performers are consistent with the α7 receptor mechanism and support further trials with CDP-choline as a potential pro-cognitive strategy for cognitive impairment in schizophrenia.
针对精神分裂症中α7烟碱型乙酰胆碱受体（α7 nAChR）功能减退的新型药物治疗，在改善与该疾病相关的认知障碍方面取得了喜忧参半的成果。胆碱是α7受体的选择性激动剂，口服胞苷5'-二磷酸胆碱（CDP-胆碱）后其含量会增加，研究人员在健康志愿者中评估了CDP-胆碱的认知效应。使用CogState测试组合，对24名男性参与者在单次低剂量（500mg）和中等剂量（1000mg）的CDP-胆碱给药后，在与精神分裂症相关的认知领域的行为表现进行了评估。相对于安慰剂，CDP-胆碱改善了低基线表现者的处理速度、工作记忆、言语学习、言语记忆和执行功能，而对中等基线表现者没有影响，对高基线表现者的认知能力则有削弱作用。剂量效应因认知领域而异，但在500mg和1000mg剂量时均很明显。这些在相对受损表现者中认知增强的初步发现与α7受体机制一致，并支持进一步试验将CDP-胆碱作为治疗精神分裂症认知障碍的潜在促认知策略。
Zotero 插件